Licensed vaccine

Fluad

FDA-licensed vaccine · Seqirus, Inc. · STN 125510

Key facts

Trade name Fluad
Proper name Influenza Vaccine, Adjuvanted
Manufacturer Seqirus, Inc.
Submission tracking number (STN) 125510
Recent FDA documents July 1, 2024 Approval Letter - FLUAD, Package Insert - FLUAD, July 2, 2021 Approval Letter - FLUAD, Statistical Review - FLUAD and FLUAD Quadrivalent, Clinical Review - FLUAD and FLUAD Quadrivalent, October 28, 2020 Approval Letter - Fluad and Fluad Quadrivalent, July 2, 2020 Approval Letter Fluad and Fluad Quadrivalent, May 13, 2020 Approval Letter - FLUAD, July 2, 2019 Approval Letter - Fluad, April 18, 2019 Approval Letter - FLUAD, July 13, 2018 Approval Letter - Fluad, Approval History, Letters, Reviews, and Related Documents - FLUAD
FDA page updated Jul 1, 2024
FDA product page fda.gov

At a glance

  • 1–9 FDA approval letters
  • 10–99 Supporting documents
  • 1–9 Product information documents
  • Yes Document full text searchable in Orca1

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About FDA-licensed vaccines

The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.

Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date:

Browse all FDA-licensed vaccines